Improving effects of olibanum on learning and memory
Phase 2
- Conditions
- Alzheimer's disease.Dementia in Alzheimer disease
- Registration Number
- IRCT20161219031463N2
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Patients with mild to moderate Alzheimer's disease based on the score of the MMSE test between 10-23
Exclusion Criteria
Diagnosis of Alzheimer's disease less than 6 months before entering the study
Using cholinesterase inhibitors and / or memantine less than 90 days before entering the study or discontinuing them less than 90 days before entering the study
Use of other drugs and substances such as ginkgo biloba or vitamin E that affect cognitive status less than 60 days before entering the study or discontinued less than 90 days before entering the study.
Vascular dementia, thyroid disease, vitamin B12 deficiency, anemia, Lewy body dementia, liver function disorders, brain tumors, ischemic cerebrovascular accidents
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive status. Timepoint: Study of cognitive status at the beginning of the study (before the intervention) and 12 weeks after the start of use of capsule containing Olibanum resin or placebo. Method of measurement: Using MMSE and CDR tests.
- Secondary Outcome Measures
Name Time Method